Treatment of BV With Donaxyl and a Molecular Test of Cure
Launched by SKARABORG HOSPITAL · Aug 14, 2019
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
This is the first study to utilize a molecular diagnostic test as a test of cure for bacterial vaginosis. The Nugent score is a reliable method for diagnosing bacterial vaginosis, but similar to traditional clinical diagnostic methods, it is not equally reliable when utilized as a test of cure. This study demonstrated that molecular diagnostic testing can be used as a test of cure and this is the first molecular test that can do that. Treatment with dequalinium chloride vaginal tablets for 6 days had a cure rate lower than expected; only 37% of patients were considered cured one month after...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • BV
- Exclusion Criteria:
- • No other infection (Gc, clhlamydia, trihomonas)
About Skaraborg Hospital
Skaraborg Hospital is a leading healthcare institution dedicated to advancing medical research and clinical practices through innovative clinical trials. With a commitment to improving patient outcomes, the hospital collaborates with multidisciplinary teams of healthcare professionals and researchers to explore new therapies and treatment protocols. By facilitating rigorous scientific investigation within a patient-centered environment, Skaraborg Hospital aims to contribute significantly to the body of medical knowledge and enhance the quality of care provided to its diverse patient population.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
P-G Larsson, PhD
Principal Investigator
överläkare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials